

Índex anglès

- absolute bioavailability, 113
absolute frequency, 466
absolute risk reduction, 750
absolute value, 846
absorption, 2
accuracy, 427
active principle, 655
active substance master file, 64
actuarial method, 563
additive model, 573
adherence, 175
adherent, 174
adjuvant, 5
adverse drug reaction, 732
adverse event, 346
adverse reaction, 732
all-or-none response, 778
allocation, 86
allocation concealment, 622
alpha level, 607
alternative hypothesis, 492
analysis of covariance, 32
analysis of variance, 33
ANCOVA, 32
ANOVA, 33
application dossier, 430
area under the ROC curve, 62
arm, 132
ARR, 750
ASMF, 64
assigned treatment, 828
assignment, 86
associate investigator, 521
association, 88
asymmetric distribution, 265
attributable risk, 786
AUC ROC, 62
audit, 93
auditor, 92
average deviation, 234

back up compound, 176
backward-elimination procedure, 667
balanced design, 257
bar chart, 237
bar diagram, 237
bar graph, 237
baseline datum, 213
basic pharmacology, 452
basic research, 737
Bayes theorem, 818
Bayesian method, 564
before and after study, 380
before-after study, 380
Behrens-Fisher problem, 666
Belmont Report, 508
benchmarking, 98
beneficence, 656
benefit to risk ratio, 765
Bernoulli distribution, 269
between-subject variation, 854
between-subjects variability, 854
bias, 99, 100

- biased estimator**, 371
bimodal distribution, 266
binary variable, 866
binomial distribution, 267
bioassay, 111
bioavailability, 112
bioavailability study, 386
biochemistry, 121
bioequivalence, 115
bioequivalence study, 387
bioethics, 117
bioinformatics, 118
biological assay, 111
biological informatics, 118
biological product, 544
biomedical ethics, 117
biomedicine, 119
biometry, 120
biopharmaceutical drug, 543
biopharmaceutical product, 543
biosimilarity, 122
biostatistics, 116
biotechnology, 123
bivariate analysis, 23
bivariate normal distribution, 281
bizarre adverse reaction, 734
blind, to, 142
blind evaluation, 94
blind trial, 67
blinded evaluation, 94
blinding, 141
block randomisation, 16
block randomization, 16
blockbuster, 551
blockbuster drug, 551
blocked randomisation, 16
blocked randomization, 16
Bonferroni correction, 195
bootstrap, 128
box plot, 238
bridging study, 416
- calibration**, 135
carrier, 428
carry-over, 309
carry-over effect, 309
- case**, 138
case history, 56
case record form, 716
case referent study, 388
case report form, 716
case-control study, 388
case-fatality rate, 814
case-series study, 405
categorical variable, 877
causal relationship, 766
CCT, 72
cell, 139
centered variable, 860
centile, 635
central tendency measure, 558
centralised authorisation
 procedure, 754
centralised community
 procedure, 754
centralized authorization
 procedure, 754
centralized community
 procedure, 754
check, to, 819
checklist, 529
chemical informatics, 723
cheminformatics, 723
chi-square, 525
chi-square distribution, 275
chi-square test, 704
chi-squared, 525
chi-squared distribution, 275
chi-squared test, 704
CHMP, 168
chronopharmacology, 209
CI, 515
circadian rhythm, 790
circular, 148
CL, 228
clearance, 228
clinical candidate, 137
clinical chart, 496
clinical data manager, 480
clinical drug development, 230
clinical equipoise, 327
clinical guideline, 681
clinical overview, 883
clinical pharmacology, 453

- clinical practice guideline**, 681
clinical project leader, 773
clinical protocol, 681
clinical record, 496
clinical relevance, 770
clinical research, 738
clinical research assistant, 87
clinical research ethics
 committee, 167
clinical significance, 802
clinical study, 379
clinical trial, 72
clinical trial application, 804
clinical trial exemption
 certificate, 673
cluster analysis, 25
cluster randomisation, 17
cluster randomization, 17
CMA, 38
Cochrane Collaboration, 163
coding dictionary, 243
coefficient of agreement, 154
coefficient of concordance, 154
coefficient of determination, 159
coefficient of variation, 161
cohort, 162
cohort effect, 305
cohort study, 390
coincidental correlation, 649
collateral effect, 304
Committee for Medicinal Products for Human Use, 168
Committee for Medicinal Products for Veterinary Use, 169
Committee for Orphan Medicinal Products, 170
common technical document, 292
community intervention trial, 80
community trial, 80
COMP, 170
comparison group, 484
compassionate use, 837
compliance, 175
compliant, 174
concurrent control group, 486
conditional probability, 664
confidence interval, 515
confidence level, 605
confidentiality, 181
confidentiality agreement, 3
confounder, 863
confounding variable, 863
contingency table, 812
continuity correction, 196
continuous variable, 861
contract research organization, 322
contributor, 150
control, 187
control group, 484
control treatment, 829
controlled clinical trial, 72
convenience sample, 594
correlation matrix, 534
cost-benefit analysis, 27
cost-effectiveness analysis, 28
cost-minimisation analysis, 38
cost-minimization analysis, 38
cost-utility analysis, 29
count, 466
covariance, 200
covariance matrix, 537
covariate, 201
Cox model, 578
Cox proportional hazards model, 578
CRA, 87
CRF, 716
criterion standard, 632
critical region, 752
critical study, 415
critical value, 847
CRO, 322
Cronbach's alpha, 19
cross-over design, 253
cross-sectional study, 422
CTA, 804
CTD, 292
CTX, 673
cumulative frequency, 467
curative dose, 298
CV, 161
CVMP, 169
- data dredging**, 824
data entry, 324

- data manager**, 480
data massage, 824
data matrix, 536
data torturing, 824
data validation, 842
DDD, 295
decentralised procedure, 756
decentralized procedure, 756
decile, 220
decision analysis, 31
Declaration of Helsinki, 221
deferred consent, 183
defined daily dose, 295
degrees of freedom, 482, 483
Delphi method, 568
Delphi technique, 568
density, 472
density function, 472
dependent variable, 865
descriptive statistics, 359
design of experiment, 258
design of experiments, 258
dichotomise, *to*, 244
dichotomize, *to*, 244
dichotomous variable, 866
digit bias, 103
directive, 248
disclaimer, 6
discrete variable, 867
disease management, 479
distribution, 264
distribution function, 473
distribution-free methods, 360
distribution-free test, 707
DMF, 64
dosage form, 461
dose, 294
dose tapering, 250
dose-escalation study, 382
dose-finding study, 403
dose-ranging study, 403
dose-response relationship, 767
dose-titration study, 381
double-blind trial, 68
double-dummy, 290
dropout, 1
drug, 440, 542
drug accountability, 745
drug candidate, 137
drug dependence, 227
drug discovery, 229
drug formulary, 490
drug master file, 64
drug metabolism, 559
drug product, 545
drug regulatory approval process, 755
drug regulatory review process, 755
drug safety, 457
drug screening, 204
drug utilisation study, 385
drug utilization study, 385
drug-drug interaction, 510
DUS, 385

EBM, 552
ecological study, 409
economic report, 555
EDMF, 64
effectiveness, 312
efficacy, 313
efficacy variable, 862
efficiency, 314
EFPIA, 459
eligible patient, 629
elimination, 317
EMA, 9
end point, 205
epidemiological study, 410
epidemiology, 325
ERC, 167
error, 330
error of the first kind, 335
error of the second kind, 336
estimate, *to*, 374
estimation, 365
estimator, 370
ethical review committee, 167
ethical standards, 660
EudraCT, 425
European drug master file, 64
European Federation of Pharmaceutical Industries and Associations, 459

European Medicines Agency, 9
event history analysis, 42
evidence-based medicine, 552
excipient, 428
exclusion criteria, 206
excretion, 317
expectation, 356
expected frequency, 468
experimental design, 258
experimental group, 488
experimental study, 411
experimental treatment, 831
expert report, 507
explanatory clinical trial, 76
explanatory variable, 872
external validity, 844

F, 433
F distribution, 274
factor, 434, 435
factor analysis, 45
factorial design, 259
false cause, 649
false negative, 438
false positive, 439
fast follower, 173
fast follower compound, 173
fast follower drug, 173
FDA, 458
Fibonacci series, 800
final report, 509
final visit, 890
financial report, 555
first-in-human clinical trial, 82
first-in-man clinical trial, 82
Fisher exact test, 703
fitting, 11
fixed-effects model, 575
follow-up, 794
follow-up visit, 888
Food and Drug Administration, 458
forward-selection procedure, 668
fourfold table, 811
frequency, 465
frequency distribution, 270
frequency polygon, 648

Friedman test, 689
fundamental pharmacology, 452
funnel plot, 236

Gaussian curve, 136
Gaussian distribution, 280
GCP, 124
generic drug, 548
genetic engineering, 323
geometric mean, 570
GLP, 126
GMP, 125
gold standard, 362
good clinical practice, 124
good laboratory practice, 126
good manufacturing practice, 125
goodness of fit, 127
goodness of fit test, 692
gradual dose reduction, 250
Graeco-Latin square, 255
Graeco-Latin square design, 255
Greco-Latin square, 255
Greco-Latin square design, 255
group randomisation, 17
group randomization, 17
guarantor, 775
guideline, 249

H2L, 672
half-life, 797
hard variable, 868
Hawthorne effect, 306
health file, 496
health outcomes research, 739
health services research, 740
health-related quality of life, 720
healthy subject, 893
healthy volunteer, 893
heteroscedasticity, 491
high-throughput screening, 203
Hippocratic oath, 524
histogram, 495
historical control study, 392
hit, 178

- hit compound**, 178
hit to lead process, 672
homoscedasticity, 497
HREC, 167
HRQL, 720
HTS, 203
human pharmacology study, 398
human research ethics
 committee, 167
hypothesis test, 683
- IC**, 182
ICH, 180
ICMJE, 171
idiosyncrasy, 501
IMP, 546
IMPD, 302
incidence, 502
inclusion criteria, 207
IND, 673
independence, 504
independent samples t-test, 711
independent variable, 872
inferential statistics, 506
information bias, 101
information leaflet, 678
informed consent, 182
initial visit, 891
INN, 222
institutional review board, 167
intent-to-treat analysis, 50
intention-to-treat analysis, 50
interim analysis, 46
internal consistency, 185
internal validity, 845
**International Committee of Medical
 Journal Editors**, 171
**International Conference on
 Harmonization**, 180
**international nonproprietary
 name**, 222
**International Union of Basic and
 Clinical Pharmacology**, 523
interpolation, 513
interquartile range, 727
interval, 514
- interval estimation**, 368
interval scale, 342
intervention, 517
intraclass correlation coefficient, 157
**investigational medicinal
 product**, 546
**investigational medicinal product
 dossier**, 302
investigational new drug, 673
investigator, 520
investigator's brochure, 301
IQR, 727
IRB, 167
ITT analysis, 50
IUPHAR, 523
- joint distribution**, 268
justice, 657
- k-way analysis of variance**, 35
Kaplan-Meier method, 565
Kolmogorov-Smirnov test, 690
Kruskal-Wallis test, 691
- large-scale trial**, 554
Lasagna's law, 526
Latin square, 256
Latin square design, 256
lead, 177
lead compound, 177
lead molecule, 177
leaflet, 678
least squares fitting, 12
least squares line, 748
least squares method, 569
**legal representative's informed
 consent**, 184
life expectancy, 355
likelihood, 882
likelihood function, 476
likelihood ratio, 729
linear model, 581

- linear regression**, 760
linear relationship, 768
log-linear model, 582
log-normal distribution, 276
logarithmic normal distribution, 276
logistic regression, 761
logit, 530
lognormal distribution, 276
logrank test, 706
loss, 636
- MAA**, 805
magistral formula, 463
Mann-Whitney U-test, 694
MANOVA, 36
Mantel-Haenszel method, 566
Mantel-Haenszel test, 695
manuscript, 291
marketing authorisation application, 805
marketing authorization
 application, 805
marketing study, 420
mask, to, 320
masking, 319
match, to, 61
matched control group, 485
matching, 60
mathematical expectation, 356
maximum likelihood method, 567
maximum tolerated dose, 296
McNemar test, 696
me-too drug, 441
mean deviation, 234
measure of dispersion, 556
measure of scatter, 556
mechanism of action, 539
MedDRA, 540
median, 541
medical deontology, 225
medical department, 226
medical device, 675
medical ethics, 424
medical file, 496
medical prescription, 735
medical record, 496
- medicinal product**, 545
megatrial, 554
memory bias, 105
meta-analysis, 561
metaregression, 562
microdosing study, 397
MID, 297
midspread, 727
minimal toxic dose, 297
minimum tolerated dose, 297
minimum toxic dose, 297
missing data, 853
missing value, 853
mixed model, 576
mixed-effects model, 576
modal value, 572
mode, 572
monitor, 587
monitoring, 588
monitoring visit, 886
monodose, 299
mortality rate, 815
MRP, 669
MTD, 296, 297
multicenter study, 412
multicenter trial, 412
multicentre study, 412
multicentre trial, 412
multilocation trial, 412
multimodal distribution, 278
multinomial distribution, 279
multiple correlation, 198
multiple regression, 762
multiplicative model, 584
multistage sampling, 601
multivariate analysis, 48
multivariate analysis of variance, 36
multivariate normal
 distribution, 283
mutual recognition procedure, 669
- n-of-one clinical trial**, 75
NBE, 618
NCE, 619
NDA, 805
negative predictive value, 849

nested case-control study, 389
new biological entity, 618
new chemical entity, 619
new drug application, 805
NNS, 612
NNT, 613
nocebo effect, 779
nocebo response, 779
nominal scale, 344
non-adherence, 503
non-adherent, 610
non-clinical overview, 884
non-compliance, 503
non-compliant, 610
non-maleficence, 658
non-parametric test, 707
non-prescription drug, 549
non-prescription product, 549
nonlinear model, 585
nonlinear regression, 763
nonlinear relationship, 769
nonparametric statistics, 360
nonparametric test, 707
normal curve, 136
normal distribution, 280
normal random variable, 874
normal range, 516
normal variable, 874
normal volunteer, 893
null hypothesis, 494
number needed to be treated, 613
number needed to screen, 612
number needed to treat, 613
Nuremberg Code, 153

O'Brien and Fleming rule, 757
observation bias, 102
observational error, 332
observational study, 413
observed frequency, 469
observer bias, 102
odds ratio, 625
off-label drug use, 838
off-label use, 838
on-ill volunteer, 893
one-sample t-test, 710

one-sided test, 714
one-tail test, 714
one-way analysis of variance, 34
open label trial, 84
open trial, 84
ordinal scale, 345
ordinal variable, 875
orphan drug, 550
OTC, 549
outcome variable, 864
outpatient, 628
over-the-counter drug, 549
over-the-counter medication, 549
overview, 63

paired data, 214
paired design, 252
paired t-test, 710
paired Wilcoxon test, 701
parallel design, 77
parallel treatment design, 77
parameter, 630
parameter estimation, 365
parametric statistics, 361
parametric test, 708
partial correlation, 199
participant, 631
patient chart, 496
patient package insert, 678
patient record, 496
PCA, 26
PDF, 472
Pearson correlation coefficient, 155
Pearson's chi-square test, 705
peer evaluation, 95
peer review, 95
per-protocol analysis, 51
percentile, 635
personal data, 215
pharmaceutical equivalence, 328
pharmaceutical form, 461
pharmaceutical medicine, 553
pharmacetics, 443
pharmacodynamics, 445
pharmacoeconomics, 446
pharmacopidemiology, 326

- pharmacogenetics**, 448
pharmacogenomics, 449
pharmacognosy, 450
pharmacokinetics, 444
pharmacological research, 741
pharmacology, 451
pharmacometrics, 455
pharmacopeia, 456
pharmacopoeia, 456
pharmacovigilance, 457
pharmacovigilance leader, 774
pharmacy, 443
phase 0 study, 397
phase I study, 398
phase II study, 399
phase III study, 400
phase IV study, 401
pie chart, 241
pie diagram, 241
PIL, 678
pilot study, 414
pivotal study, 415
placebo, 640
placebo effect, 780
placebo reactor, 776
placebo responder, 776
placebo response, 780
play-the-winner design, 251
PMS, 396
point estimate, 369
Poisson distribution, 272
population, 642, 646
positive predictive value, 850
post hoc, 649
post hoc ergo propter hoc, 649
postapproval study, 417
postmarketing drug surveillance study, 396
postmarketing study, 396
postmarketing surveillance study, 396
power, 650
PP analysis, 51
pragmatic clinical trial, 78
pragmatic trial, 78
pre-randomisation visit, 887
pre-randomization visit, 887
precision, 651
preclinical drug development, 231
preclinical research, 737
preclinical study, 419
prevalence, 654
primary endpoint, 205
primary objective, 620
primary outcome variable, 205
principal components analysis, 26
principal investigator, 522
probabilistic, 13
probabilistic model, 579
probability, 663
probability density function, 472
probability distribution, 273
probability function, 474
probit, 665
procedure manual, 532
prodrug, 676
product information leaflet, 678
professional inspection, 95
prognostic indicator, 436
proof of concept, 687
proof of concept study, 687
proportional hazards model, 578
prospectus, 678
proteomics, 679
protocol, 680
protocol amendment, 349
publication bias, 107

QALY, 59
QAU, 834
QoL, 719
QOS, 782
qualitative interaction, 511
qualitative variable, 877
quality assurance, 85
quality assurance unit, 834
quality control, 188
quality of life, 719
quality of life measure, 557
quality overall summary, 782
quality-adjusted life years, 59
quantile, 721
quantitative interaction, 512
quantitative variable, 878

- quartile, 722
quartile deviation, 728
- R & D, 742
random, 13
random error, 331
random experiment, 432
random number, 611
random sample, 591
random variable, 857
random-effects model, 574
randomisation, 14
randomisation code, 152
randomisation list, 527
randomisation visit, 885
randomised clinical trial, 73
randomised consent design
 trial, 378
randomization, 14
randomization code, 152
randomization list, 527
randomization visit, 885
randomized clinical trial, 73
randomized consent design
 trial, 378
rank, 726
rank-sum test, 693
rate, 813
ratio, 731
ratio scale, 343
raw data, 216
REB, 167
recall bias, 105
receiver operating characteristic
 curve, 191
recruitment, 744
recruitment period, 637
refereeing, 95
reference drug, 442
reference population, 643
regression, 758
regression coefficient, 160
regression curve, 190
regression line, 749
regression to the mean, 759
regression towards the mean, 759
- rejection region, 752
relative bioavailability, 114
relative error, 338
relative frequency, 470
relative odds, 625
relative risk, 787
relative risk reduction, 751
reliability, 460
repeated-dose study, 393
reporting bias, 106
reproducibility of results of
 measurements, 771
rescue therapy, 830
research, 736
research and development, 742
research ethics board, 167
researcher, 520
residual, 772
respect for autonomy, 659
response, 777
response bias, 109
response variable, 864
retrospective study, 421
review, 63
risk difference, 245
risk factor, 437
risk-benefit ratio, 765
robustness, 791
ROC curve, 191
root mean square deviation, 233
RR, 787
RRR, 751
run-in period, 639
- safety, 795
safety study, 404
salvage therapy, 830
sample, 590, 597
sample, to, 602
sample attrition, 91
sample size, 481
sample size calculation, 134
sampling, 599
sampling fraction, 464
sampling unit, 835
scatter diagram, 239

scatter plot, 239
scatterplot, 239
screening, 202
SD, 233
SE, 337
secondary drug effect, 310
secondary objective, 621
secrecy agreement, 3
seeding study, 420
selection bias, 110
selection visit, 891
selectivity, 796
semi-interquartile range, 728
sensitivity, 798
sensitivity analysis, 39
sequential analysis, 53
sequential design, 79
serendipity, 799
serious adverse event, 347
sign test, 702
significance, 803
significance level, 607
significance test, 698
simple random sample, 593
simple random sampling, 600
simple randomisation, 18
simple randomization, 18
simple regression, 764
single center study, 423
single center trial, 423
single centre study, 423
single centre trial, 423
single dose, 299
single unit package, 300
single-blind trial, 69
single-dose study, 394
single-subject clinical trial, 75
skewed distribution, 265
SOP, 670
SPC, 781
Spearman correlation
 coefficient, 156
Spearman rank correlation
 coefficient, 156
specificity, 353
sponsor, 677
spontaneous adverse reaction
 reporting, 617

standard deviation, 233
standard drug, 442
standard error, 337
standard operating procedure, 670
standardisation, 363
standardise, to, 364
standardised mean difference, 247
standardised variable, 869
standardization, 363
standardize, to, 364
standardized mean difference, 247
standardized variable, 869
statement of investigator, 179
statistic, 357
statistical analysis, 44
statistical model, 579
statistical significance, 803
statistically significant
 difference, 246
statistics, 358
step-down procedure, 667
step-up procedure, 668
stepwise procedure, 671
stochastic, 13
stochastic model, 579
stochastic variable, 857
stratification, 377
stratified randomisation, 15
stratified randomization, 15
stratified sample, 592
stratum, 376
Student's t, 808
Student's t-distribution, 286
Student's t-test, 709
study arm, 132
study treatment, 831
subgroup analysis, 41
subinvestigator, 521
subject, 631
subsample, 807
summary of product
 characteristics, 781
surrogate endpoint, 879
surrogate marker, 879
surrogate variable, 879
survival analysis, 42
survival curve, 192
survival function, 475

- survival rate**, 816
symmetric distribution, 285
systematic review, 785
systematic sample, 596
- tachyphylaxis**, 809
tail, 210
target, 242
target population, 645
test, to, 819
test group, 488
test of homogeneity, 684
test of independence, 685
test of normality, 697
therapeutic confirmatory study, 400
therapeutic dose, 298
therapeutic equivalence, 329
therapeutic exploratory study, 399
therapeutic use study, 401
tie, 321
time series analysis, 40
tolerability, 822
tolerability study, 406
tolerance, 823
tolerance study, 407
toxicity, 825
toxicity test, 408
toxicology, 826
treatment, 827
trial subject, 631
trialist, 631
triple-blind trial, 70
two-by-two contingency table, 811
two-by-two table, 811
two-samples t-test, 711
two-sided test, 682
two-tails test, 682
type A adverse reaction, 733
type B adverse reaction, 734
type I error, 335
type II error, 336
- U.S. Food and Drug Administration**, 458
unbalanced design, 260
unbiased estimator, 372
unexpected adverse event, 348
unicenter study, 423
unicenter trial, 423
unicentre study, 423
unicentre trial, 423
unidose, 299
uniform distribution, 287
unimodal distribution, 288
unit dose, 300
univariate analysis, 54
universe, 642
unlabeled drug use, 838
unlabeled use, 838
unlabelled drug use, 838
unlabelled use, 838
unmasked trial, 84
- vaccine**, 840
validation, 841
validation of data, 842
validity, 843
variable, 856
variance, 881
variance-covariance matrix, 537
verify, to, 819
volunteer, 892
- washout**, 638
washout period, 638
weighted average, 571
weighted mean, 571
WHO, 627
Wilcoxon rank-sum test, 693
Wilcoxon signed-rank test, 701
withdrawal, 783
within-subject variability, 855
working hypothesis, 493
World Health Organization, 627

Yates' correction, 196

Zelen's design, 378

α risk, 788

β risk, 789